Table 1.

Clinical parameters of patients

	Control	PDAC			CP
		non-cachexia	cachexia	p	non-cachexia	cachexia	p
N	13	23	13		19	6	ns
Female	6 (46%)	11 (48%)	6 (46%)	ns	10 (53%)	2 (33%)
Male	7 (54%)	12 (52%)	7 (54%)		9 (47%)	4 (67%
Age, years	63 (19–78)	68 (41–88)	61 (52–77)	ns	50 (36–77)	49 (44–73)	ns
UICC stage	nr	I 2 (9%)		ns	nr	nr
		II 16 (70%)	II 5 (38%)
		III 2 (9%)	III 1 (8%)
		IV 3 (12%)	IV 7 (54%)
ASA I	18%	7%	9%	ns	23%		ns
II	73%	64%	64%		46%	67%
III	9%	29%	27%		31%	33%
Jaundice	0 (0%)	5 (22%)	5 (38%)	ns	0 (0%)	1 (17%)	ns
Weight loss, kg	0.0 (0)	2 (0–8)	12,5 (6–34)	< 0.001#	0 (0–6)	12,5 (8–40)	< 0.001##
Weight loss, %	0.0 (0)	3.0 (0–9.2)	14.0 (10.0–26.6)	< 0.001#	0 (0–9.1)	15.7 (11.1–28.6)	< 0.001##
Perirenal fat, mm	15.2 (6.7–32.5)	11.0 (2.0–39.0)	11.6 (4.0–26.2)	ns	6 (2.5–22.4)	7.0 (5.2–19.1)	0.013§§
M. erector spinae, mm	36.2 (28.9–39.8)	30.3 (18.7–39.1)	31.1 (26.0–41.4)	ns	32.1 (24.3–47.4)	40.5 (36.7–45.1)	0.019##
M. psoas, mm	37.0 (30.6–53.8)	38.0 (25.1–43.5)	32.8 (25.0–39.5)	ns	37.9 (20.7–51.2)	28.8 (22.6–35.7)	0.030°°
							0.039##
M. psoas area, mm2	1044,2 (876,2–1997,0)	1022,1 (608,7–1371,8)	702,1 (527,3–1075,2)	0.035°	943,5 (345,7–1971,5)	714,4 (565,9–931,3)
				0.031#
Subcutaneous fat medial, mm	17.8 (6.7–62.6)	14.0 (3.0–60.6)	20.7 (1.1–50.4)	ns	8.2 (0.6–62.3)	6.3 (2.5–31.2)
Subcutaneous fat lateral, mm	45.0 (29.1–92.0)	37.1 (14.9–77.5)	38.3 (7.7–72.4)	ns	33.5 (4.3–94.5)	34.6 (22.3–45.3)

Values are demonstrated as median (minimum-maximum)

ns not significant; nr not relevant

° PDAC with cachexia versus control; # PDAC without cachexia versus PDAC with cachexia

§§ CP without cachexia versus control; °° CP with cachexia versus control; ## CP without cachexia versus CP with cachexia